医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Annie Hai-yuan Lo Elected to Quintiles Transnational Holdings Inc. Board of Directors

2015年09月29日 AM05:30
このエントリーをはてなブックマークに追加


 

RESEARCH TRIANGLE PARK, N.C.

Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) announced today that Annie Hai-yuan Lo, has been appointed to its Board of Directors, effective immediately. Ms. Lo will also serve as a member of the Audit Committee of the Board.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150928005145/en/

Annie Hai-yuan Lo, Quintiles Board of Directors (Photo: Business Wire)

Annie Hai-yuan Lo, Quintiles Board of Directors (Photo: Business Wire)

Ms. Lo has more than 30 years of financial and operational experience at Johnson & Johnson, a global healthcare company, most recently serving as the Chief Financial Officer of the Worldwide Consumer & Personal Care Group from 2001 until her retirement in 2011. Ms. Lo serves as a director of Ansell Ltd., an Australian manufacturing company, and TransForce Inc., a Montreal-based transportation and logistics company.

Ms. Lo received her Bachelor’s Degree in Taiwan from National Taiwan University and her Masters of Business Administration from Eastern Michigan University. She is a Certified Management Accountant.

About Quintiles

Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.

Click here to subscribe to Mobile Alerts for Quintiles.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150928005145/en/

CONTACT

Quintiles Transnational Holdings Inc.
Phil Bridges, Media Relations
(phil.bridges@quintiles.com)
+
1.919.998.1653 (office) +1.919.457.6347 (mobile)
or
Todd
Kasper, Investor Relations (InvestorRelations@quintiles.com)
+1.919.998.2590

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • AGICキャピタルがATECファーマテクニックの過半数持ち分を取得
  • Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
  • 辉凌基于微生物群的首创活体生物治疗药物REBYOTA®(粪便微生物群,live-jslm)获得美国FDA批准
  • Bio-Thera Solutions Announces Presentation of BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Selection Summit
  • Bio-Thera Solutions Announces BAT8006 (Folate-Receptor-α-ADC) and BAT8008 (Trop2-ADC) Poster Presentations at the 2022 San Antonio Breast Cancer Symposium